[Google Scholar] [CrossRef] Ayyasamy V, Owens KM, Desouki MM, Liang P, Bakin A et al
Studies: The SURPASS clinical trial program, which tested tirzepatide in various dosages, showed that participants lost a significant amount of weight, and many achieved a weight reduction of 15% or more
(2023) revealed that the gut microbiota of CKD patients, even at the early stages of the disease, show some distinct alterations in relation to those of the healthy controls
Smoking and neuropsychiatric Disease-associations and underlying mechanisms
Primary Research Areas NNMT enzymology and pharmacology the lead first-in-class selective small-molecule NNMT inhibitor used to validate the entire target class [1,2]
Users must avoid UV exposure sufficient to cause erythema (redness)